New prospects for lipid-lowering drugs. - Wikidata - awgldk - TriplyDB

New prospects for lipid-lowering drugs.

New prospects for lipid-lowering drugs.

http://www.wikidata.org/entity/Q40408992

about

Novel lipid-regulating drugs.

P2860

Q34075175-E57E7DFC-9174-4869-91CD-B878063F2254

P2860

New prospects for lipid-lowering drugs.

http://www.wikidata.org/entity/Q40408992

description

1998 nî lūn-bûn

@nan

1998年の論文

@ja

1998年論文

@yue

1998年論文

@zh-hant

1998年論文

@zh-hk

1998年論文

@zh-mo

1998年論文

@zh-tw

1998年论文

@wuu

1998年论文

@zh

1998年论文

@zh-cn

name

New prospects for lipid-lowering drugs.

@en

type

label

New prospects for lipid-lowering drugs.

@en

prefLabel

New prospects for lipid-lowering drugs.

@en

P1433

Q40408992-B4E4E164-A242-4F76-B9D6-4ED9F3234800

P1476

Q40408992-CF80FA9A-04A4-413E-A803-91D5DD07519F

P2093

Q40408992-76BC10A6-86E1-4F54-B67E-3DFE0A20715C

Q40408992-AFFB1670-C56E-4592-910A-E6C2E45E11D4

P2860

Q40408992-09808DA4-69D6-4072-B80C-1FB744F10FAB

Q40408992-17880DF9-09F6-4225-9BF9-EE87E1FD01A8

Q40408992-2E4BAB1C-6DEA-421E-90C6-70D7B7F8CB94

Q40408992-34F7AE92-77EA-478D-8E99-477B05BB7CD6

Q40408992-460C4C48-14E7-47B9-8ABB-37A4F227B01F

Q40408992-4AF87CC9-315B-4834-98F6-470CF9D301F8

Q40408992-57FB2696-238C-43FB-A941-160F09851BA2

Q40408992-58F9BC50-F225-4111-8EC9-7533F4E6FA8E

Q40408992-6768A21D-7E3A-4835-A965-B8701AE702F1

Q40408992-6DCDBFD8-EADC-49B2-A266-E7789F21B2B6

P304

Q40408992-A22D8345-665C-4133-A339-5025DF40C4E3

P31

Q40408992-243ED89A-C210-45C8-A4F4-6F6AADA53D57

P356

Q40408992-50FEFC97-D814-4A27-B8BA-534123654D2B

P407

Q40408992-CFD9B1CD-A09D-43B8-87A2-CF5321BF94CA

P433

Q40408992-EAB7B8C5-C539-42A0-86A0-CEFFF213BE5D

P478

Q40408992-E11157C2-5006-421F-9A29-FE34B9ED167C

P577

Q40408992-CC0AD4A1-0E75-4B95-B072-2B21BBA6592E

P698

Q40408992-0D0B3C8B-2EDB-49E3-A71E-1A8351D3FE76

P356

13543784.7.5.715

P1433

Expert Opinion on Investigational Drugs

P1476

New prospects for lipid-lowering drugs.

@en

P2093

Naoumova RP

http://www.w3.org/2001/XMLSchema#string

Thompson GR

http://www.w3.org/2001/XMLSchema#string

P2860

Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

CHOLESTYRAMINE RESIN THERAPY FOR HYPERCHOLESTEREMIA: CLINICAL AND METABOLIC STUDIES.

Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor.

Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia.

Atorvastatin: an effective lipid-modifying agent in familial hypercholesterolemia.

Cerivastatin: pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor.

Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR.

Cholesteryl ester transfer protein: friend or foe?

Effect of bezafibrate treatment over five years on coronary plaques causing 20% to 50% diameter narrowing (The Bezafibrate Coronary Atherosclerosis Intervention Trial [BECAIT]).

P304

715-727

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543784.7.5.715

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

1998-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15991963

http://www.w3.org/2001/XMLSchema#string